Regenerative Medical Technology (RMTG) Free Cash Flow (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Free Cash Flow of -$213270.0 for Q1 2026, down 473.44% year-over-year from $57109.0 in Q1 2025, and up 6.86% quarter-over-quarter from -$228976.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Free Cash Flow (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Free Cash Flow history runs 9 years deep, the most recent figure standing at -$213270.0 for Q1 2026.
- In Q1 2026, Free Cash Flow fell 473.44% year-over-year to -$213270.0; the TTM figure through Mar 2026 stood at -$1.5 million (down 328.24% YoY), while the FY2025 annual figure was -$1.3 million, down 306.07% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$213270.0, up from -$228976.0 in the prior quarter.
- The five-year high for Free Cash Flow was $329393.0 in Q4 2024, with the low at -$598093.0 in Q2 2025.
- The 5-year median for Free Cash Flow is -$153437.0 (2022), against an average of -$162660.6.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 3686.81% in 2024, then sank 1684.73% in 2025.
- Regenerative Medical Technology's Free Cash Flow stood at -$117957.0 in 2022, then plunged by 165.69% to -$313401.0 in 2023, then jumped by 205.1% to $329393.0 in 2024, then slumped by 169.51% to -$228976.0 in 2025, then rose by 6.86% to -$213270.0 in 2026.
- Business Quant data shows RMTG's Free Cash Flow at -$213270.0 in Q1 2026, -$228976.0 in Q4 2025, and -$428560.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | -213,270.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -213,270.00 |
| Mar 31, 2026 | -213,270.00 |
| Dec 31, 2025 | -228,976.00 |
| Dec 31, 2025 | -228,976.00 |
| Sep 30, 2025 | -428,560.00 |
| Sep 30, 2025 | -428,560.00 |
| Jun 30, 2025 | -598,093.00 |
| Jun 30, 2025 | -598,093.00 |
| Mar 31, 2025 | 57,109.00 |
| Mar 31, 2025 | 57,109.00 |
| Dec 31, 2024 | 329,393.00 |
| Dec 31, 2024 | 329,393.00 |
| Sep 30, 2024 | 219,334.00 |
| Sep 30, 2024 | 219,334.00 |
| Jun 30, 2024 | 37,741.00 |
| Jun 30, 2024 | 37,741.00 |
| Mar 31, 2024 | 48,812.00 |
| Mar 31, 2024 | 48,812.00 |
| Dec 31, 2023 | -313,401.00 |
| Dec 31, 2023 | -313,401.00 |